Study drug for lung cancer with specific c-MET changes
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests ABN401 to see how well it works and how safe it is for people with advanced non-small cell lung cancer (NSCLC) that has certain c-MET (a protein) changes. It may help some tumors that have not responded well to prior treatment, especially certain EGFR-related cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older (or the local adult age of majority).
- Your health status is ECOG 0–1 (you can do most daily activities).
- You have at least 1 measurable lung tumor spot on scans.
- Your cancer must be NSCLC that has spread or returned, and it must match one of the trial’s c-MET/EGFR situation groups.
- You can’t have had prior c-MET (MET) inhibitor medicines or HGF-targeting treatments.
- You must be able to provide required tumor tissue and blood samples (fresh or stored tissue is often allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CKD-703 for people with advanced solid tumors, including a type of lung cancer (non-small cell lung cancer) that has a specific marker called c-Met. The study aims to see if the drug is safe and effective for those who have already tried other treatments that didn't work or caused side effects.
This Phase 2 trial tests whether a c-MET inhibitor can slow or shrink advanced solid tumors that have specific c-MET genetic changes. You may be eligible if your cancer has progressed after standard treatment and you meet safety and heart/health requirements.
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.